0001104659-22-020895.txt : 20220211
0001104659-22-020895.hdr.sgml : 20220211
20220211213450
ACCESSION NUMBER: 0001104659-22-020895
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220209
FILED AS OF DATE: 20220211
DATE AS OF CHANGE: 20220211
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shulman Joseph
CENTRAL INDEX KEY: 0001909855
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 22624299
MAIL ADDRESS:
STREET 1: C/O RHYTHM PHARMACEUTICALS
STREET 2: 222 BERKELEY STREET, SUITE 1200
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
tm226394-6_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-02-09
0
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0001909855
Shulman Joseph
C/O RHYTHM PHARMACEUTICALS, INC.
222 BERKELEY STREET, 12TH FLOOR
BOSTON
MA
02116
0
1
0
0
Chief Technical Officer
Restricted Stock Units
2022-02-09
4
A
0
10625
0
A
Common Stock
10625
10625
D
Stock Option (Right to Buy)
6.80
2022-02-09
4
A
0
63750
0
A
2032-02-08
Common Stock
63750
63750
D
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
The restricted stock units vest as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date.
The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
/s/ Hunter Smith, Attorney-in-Fact for Joseph Shulman
2022-02-11